Julie Papanek Grant - Jul 1, 2022 Form 4/A - Amendment Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Charles N. York II, Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Jul 1, 2022
Transactions value $
-$36,000
Form type
4/A - Amendment
Date filed
7/12/2022, 09:14 PM
Date Of Original Report
Jul 6, 2022
Previous filing
Jun 23, 2022
Next filing
Jul 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Sale -$20K -1K -0.22% $20.00 464K Jul 1, 2022 See Footnote F1, F2
transaction DAWN Common Stock Sale -$16K -800 -0.17% $20.00 463K Jul 5, 2022 See Footnote F1, F2
holding DAWN Common Stock 362 Jul 1, 2022 See Footnote F3
holding DAWN Common Stock 9.66M Jul 1, 2022 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021.
F2 Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or for any other purpose.
F3 This amendment to Form 4 is filed to include holdings by The Adam and Julie Grant Revocable Trust dtd October 13, 2017 (the "Revocable Trust"), of which the Reporting Person and her spouse are co-trustees, that were inadvertently omitted from the Form 4 filed on July 6, 2022. These shares were received by the Revocable Trust in one or more prior distributions-in-kind by Canaan XI L.P. for no consideration pursuant to the exemptions afforded by Rules 16a-9 and 16a-13 of the Act. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
F4 Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.